Novartis AG (NYSE: NVS) will pay $245 million to end antitrust litigation accusing the company of trying to delay the U.S. launch of generic versions of its Exforge, which treats hypertension to lower blood pressure and reduce the risk of strokes.
Current is an Andreessen Horowitz-backed disruptor looking to fix the way people bank.
“On one hand, there’s currency debasement and its inflationary impacts," the firm's CTO, Trevor Marshall, says. "On the other hand, you have technology which is a deflationary force putting people out of work.”
CVS Health's (NYSE:CVS) short percent of float has risen 4.95% since its last report. The company recently reported that it has 13.92 million shares sold short, which is 1.06% of all regular shares that are available for trading.
With the coming of the winter season, federal data shows that flu infections and hospitalizations are rising, in addition to an already busy season for other respiratory viruses, including respiratory syncytial virus.
Simultaneously, Covid-related hospitalizations have increased in recent weeks, though slightly lower than the last year.
Shares of CVS Health Inc. (NYSE:CVS) decreased by 0.13% in the past three months. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its financials.